Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Teladoc

Companies working to bring us to the other side of the pandemic might be the biggest winners.

3 Mega-Trends Healthcare Investors Should Watch Right Now

In every crisis and challenge rests great opportunity.

3 Silver Linings for the Healthcare Sector in 2020

Abbott's recent Q4 2020 was a thing of beauty with strong forward guidance. The company's COVID-19 tests will serve the company well, even as/if the pandemic eases.

Abbott: Ballast Your Portfolio - Q4 2020 Earnings Edition

The shares of Abbott Laboratories (NYSE: ABT) have received a price target increase from $113 to $140 by Cowen. These are the details.

ABT Stock Price: $140 Target (Up From $113) By Cowen

A top Wall Street analyst increased the price target for the healthcare giant.

Why Abbott Labs Stock Is Jumping Today

BlackBerry

Microsoft

Texas Instruments

BlackBerry, Microsoft, Abbott Labs and Texas Instruments were our top stock trades for Thursday. Now, let's look at the charts.

4 Top Stock Trades for Thursday: BB, MSFT, ABT, TXN

Two words tell the story: coronavirus testing.

Here's How Abbott Labs Hit a Home Run With Its Q4 Results

Ford Motor Company

Abbott Laboratories (ABT) CEO, Robert Ford on Q4 2020 Results - Earnings Call Transcript

Within Diabetes Care, Abbott (ABT) reports strong sales banking on growing demand for sensor-based continuous glucose monitoring system, FreeStyle Libre.

Abbott (ABT) Q4 Earnings Top, Diagnostic Test Sales Solid

Abbott Laboratories said Wednesday fourth-quarter diagnostics sales doubled on the back of booming demand for Covid-19 tests. In response, ABT stock inched higher.

Abbott Stock Jumps As Coronavirus Tests Drive Quarterly Diagnostics Boom

Abbott (ABT) delivered earnings and revenue surprises of 6.62% and 8.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Beats Q4 Earnings and Revenue Estimates

Abbott Laboratories (NYSE: ABT) published its earnings report for the fiscal fourth quarter on Wednesday that came in better than what analysts had anticipated. The company attributed its hawkish performance to robust demand for its COVID-19 tests amidst the pandemic that has so far infected more than 26 million people in the United States and […] The post Abbott Laboratories beats Wall Street estimates in the fourth quarter appeared first on Invezz.

Abbott Laboratories beats Wall Street estimates in the fourth quarter

Shares of Abbott Laboratories (NYSE:ABT) moved lower by 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.63% year over year to $1.45, which beat the estimate of $1.35.

Abbott Laboratories: Q4 Earnings Insights

Shares of Abbott Laboratories were down 0.8% in premarket trading on Wednesday as surging revenue for its COVID-19 tests carried the company past earnings and sales estimates. Abbott had earnings of $2.1 billion, or $1.20 per share, in the fourth quarter of 2020, up from $1.0 billion, or 59 cents per share, in the same quarter a year ago.

Abbott beats sales estimates as rapid diagnostics business now generates one-fourth of revenue

ABBOTT PARK, Ill., Jan. 27, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2020, and issued its financial outlook for 2021. Fourth-quarter sales of $10.7 billion increased 28.7 percent on a reported basis and...

Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

Danaher

Johnson Controls

ServiceNow

Stanley Black & Decker

It's not easy to beat every quarter on earnings for five years, including during a global pandemic. These companies have done it.

5 Incredible Perfect Earnings Charts

Abbott stock (NYSE: ABT) is scheduled to report its Q4 2020 results on Wednesday, January 27. We expect Abbott to likely report mixed results with revenues slightly below and earnings in-line with the consensus estimates, driven by a rebound in demand for medical devices.

Can Abbott Stock Trade Higher Post Q4 Results?

ABBOTT PARK, Ill., Jan. 26, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has received CE Mark for two new uses of its Panbio™ COVID-19 Ag Rapid Test Device for the detection of the SARS-CoV-2 virus: asymptomatic testing and self-swabbing. Panbio COVID-19 Ag's label has been...

Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab

Johnson & Johnson

3 COVID Stocks to Buy if You're Not a Big Risk-Taker

Becton, Dickinson and Co.

Cardinal Health

Medtronic

Healthcare aristocrats benefit from significant medical device contributions. By and large these healthcare aristocrats share favorable quant metrics on Seeking Alpha, albeit with significant variations among the five.

Medical Device Aristocrats For A High Class Dividend Portfolio

Within EPD, Abbott (ABT) is expected to have witnessed visible signs of rebound through Q4.

Demand for COVID-19 Tests to Drive Abbott (ABT) Q4 Earnings

ABBOTT PARK, Ill., Jan. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as...

Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device

Health Care Select Sector SPDR Fund

Nearby levels of support and recent closes beyond key resistance are creating lucrative risk/reward setups in the healthcare sector.

Healthcare Stocks Appear Set to Move Higher

Hologic

QuidelOrtho Corp

The Department of Health and Human Services (HHS) promises over $22 billion of funding.

Federal, Private Tie-Ups Boost COVID-19 Testing Volume

AdvisorShares Focused Equity ETF

Eagle Bancorp

Globe Life Inc

HEICO

Hormel Foods

Miller Industries

RPM International

Thermo Fisher Scientific

Zoetis

Welcome to Alpha Trader. We have a special double bill today in honor of wildcard weekend coming up on the show. Eddy Elfenbein of Crossing Wall Street giving us his top five new stocks for 2021. But first we are pleased to welcome back to the show, Ryan Detrick. He is Chief Market Strategist for LPL Financial. Ryan, welcome back to Alpha Trader.

News for Abbott Labs Stock (ABT)